Literature DB >> 14725671

Full-face carbon dioxide laser resurfacing in the management of a patient with the nevoid basal cell carcinoma syndrome.

Alexander Doctoroff1, Steven A Oberlender, Stephen M Purcell.   

Abstract

BACKGROUND: Multiple surgical procedures are often a source of discomfort, pain, and disfigurement for patients with the nevoid basal cell carcinoma syndrome (NBCCS).
OBJECTIVE: The patient with NBCCS had approximately 45 identifiable basal cell carcinomas on her face. Multiple Mohs surgeries were performed to remove the largest tumors. A tumor-free plane was not achieved in several lesions despite removal of multiple tissue layers. The treatment of the remaining tumors presented a significant challenge.
METHODS: Full-face CO2 laser resurfacing was performed after curettage and local laser ablation of all visible tumors.
RESULTS: The patient healed well postoperatively. She developed six basal cell carcinomas on her face during the 10-month follow-up period. These were easily treated with Mohs surgery and imiquimod cream.
CONCLUSION: CO2 laser resurfacing is a useful surgical modality for treatment of multiple facial basal cell carcinomas in the patients with NBCCS. It allows treatment of all the facial lesions in a single session and minimizes suffering resulting from repeated surgical procedures. Additionally, the layer of skin damaged by ultraviolet radiation is removed, allowing for easier management after resurfacing.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14725671     DOI: 10.1111/j.1524-4725.2003.29395.x

Source DB:  PubMed          Journal:  Dermatol Surg        ISSN: 1076-0512            Impact factor:   3.398


  2 in total

Review 1.  Nevoid basal cell carcinoma syndrome (Gorlin syndrome).

Authors:  Lorenzo Lo Muzio
Journal:  Orphanet J Rare Dis       Date:  2008-11-25       Impact factor: 4.123

2.  Skin tags as a presenting sign of basal cell nevus syndrome in three sisters of the same family.

Authors:  Yousef Alghamdi
Journal:  Ann Saudi Med       Date:  2008 Mar-Apr       Impact factor: 1.526

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.